Pharmaceuticals, Biotechnology & Life Sciences

Avant Brands Inc. faces a tough road ahead: handcrafted Canadian cannabis quality clashes with a negative P/E and volatile stock, raising key questions about strategy and profitability.

Discover why VERADERMICS INC’s stock volatility, negative P/E, and opaque operations are raising red flags for investors in the fast‑moving healthcare sector.

Discover how Bayer’s Supreme Court win reshapes its legal, market, and credit outlook—uncover risks, rally potential, and future growth strategies.

Jiangsu Hengrui Pharma’s robust drug pipeline and rising policy support position it to capture China’s expanding anti‑cancer market, boosting investor confidence.

Harbin Pharmaceutical’s three‑board surge shows rising investor confidence in China’s pharma sector—yet highlights risks of high valuation and thin margins.

Quantum Cyber NV’s stable €8 share price and negative P/E highlight its biotech focus on rapid, molecular‑genetic diagnostics that aim to transform global patient care.

Unicycive Therapeutics advances novel hyperphosphatemia treatments for CKD and AKI, aiming to curb complications and attract investors with a promising pipeline.

Tilray Brands Inc. gears up for July 28 earnings, weighing cannabis volatility, a BrewDog pub event, and a downgraded analyst outlook.

SPRO: Spero Therapeutics secures a $1.1B licensing deal for anti‑CD40L antibody IBI355 and a $105M royalty financing, boosting its IgG4‑RD and Sjögren’s disease pipeline.

Explore how Celyad Oncology’s cutting‑edge CAR‑T therapy is reshaping cancer treatment worldwide, boosting hope for aggressive cancers with limited options.